Serum biomarkers of fibrosis and viral hepatitis B

The eLIFT and FIB-4 scores offered the best diagnostic performance, with high sensitivity and specificity for detecting advanced fibrosis and cirrhosis. eLIFT showed a remarkable ability to predict advanced stages of fibrosis thanks to the integration of several parameters. APRI and King Score showed good results, but with lower specificity for advanced stages. These non-invasive serum biomarkers, in particular eLIFT and FIB-4, are proving to be reliable alternatives to invasive methods, enabling faster, more accessible and less costly diagnosis, particularly in resource-limited settings.